Stem Cell Viability Testing: Methods, Standards, and Quality Control Applications

Stem cell viability testing quantifies the proportion of living, functional cells in a stem cell preparation and serves as a fundamental release criterion for cell therapy manufacturing, cell banking, and translational research. Accurate viability data safeguard product quality, support regulatory compliance with standards such as ISO 20391-1 and ASTM F2944, and guide process optimization across the cell processing workflow. This technical article explains the principles, sample types, testing items, analytical methods, and practical applications of stem cell viability testing, along with answers to frequently asked questions.

Technical Overview

Stem cell viability testing is a quantitative quality control procedure that determines the fraction of cells within a stem cell suspension that remain alive and functionally competent. Cell viability is not a single property but a composite indicator that reflects membrane integrity, metabolic activity, and the capacity for proliferation. A cell population may contain fully viable cells, cells undergoing early apoptosis, cells in late-stage apoptosis with compromised membranes, and fully necrotic cells, and a scientifically sound viability assay should distinguish among these states.

In the context of cell-based therapeutics, viability is a critical quality attribute (CQA) directly linked to product safety and potency. Regulatory expectations worldwide require documented viability results before the release of cell therapy products, and accredited third-party laboratories routinely perform these analyses under quality management systems aligned with ISO/IEC 17025. Key reference frameworks include ISO 20391-1 for cell counting and viability determination, ASTM F2944 for the quantification of cell counts and viability using automated or manual methods, and applicable GB/T standards for biotechnology cell counting in regional markets such as China.

A typical viability test report includes total cell count, viable cell count, viability percentage, and interpretive notes on assay suitability. Because different measurement principles respond to different aspects of cell physiology, orthogonal methods are often combined—for example, dye exclusion for membrane integrity, flow cytometry for apoptosis staging, and metabolic assays for functional competence.

Testing Samples

Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells isolated from bone marrow, adipose tissue, umbilical cord, Wharton's jelly, or dental pulp are among the most frequently tested sample types. Testing is typically performed at harvest, after passage, post-wash, post-formulation, and immediately after thawing of cryopreserved lots. MSC viability directly influences colony-forming ability, immunomodulatory function, and downstream manufacturing yield.

Hematopoietic Stem and Progenitor Cells (HSCs)

Cord blood units, bone marrow aspirates, mobilized peripheral blood apheresis products, and processed HSC grafts require viability assessment before infusion or long-term cryostorage. Post-thaw viability of CD34-positive populations is a particularly important metric, since cell loss during freezing and thawing correlates with engraftment performance.

Pluripotent Stem Cells (ESCs and iPSCs)

Embryonic stem cells and induced pluripotent stem cells are sensitive to single-cell dissociation and passaging, making routine viability monitoring essential. Testing supports master cell bank qualification, clonal line expansion, differentiation protocol development, and quality checks before use in disease modeling or cell derivative production.

Intermediate and Final Cell Products

Cryopreserved vials, culture harvests, concentrated cell suspensions, spheroids, organoids, and cell-laden scaffold or hydrogel constructs can all be submitted for viability evaluation. For three-dimensional samples, enzymatic or mechanical dissociation, or non-destructive imaging-based approaches, may be applied depending on the matrix and measurement objective.

Testing Items

Standard testing panels for stem cell viability typically include the following measurable items:

• Total nucleated cell count and viable cell count (cells/mL)
• Viability percentage (viable cells relative to total counted cells)
• Cell diameter and size distribution, used to cross-check cell identity and debris contamination
• Membrane integrity status, distinguishing intact, compromised, and fully lysed cells
• Apoptosis and necrosis staging, reported as viable, early apoptotic, late apoptotic, and necrotic fractions
• Metabolic activity indices such as mitochondrial dehydrogenase activity or intracellular ATP levels
• Post-thaw recovery rate for cryopreserved samples, comparing pre-freeze and post-thaw viable cell numbers
• Viability of specific subpopulations, for example viability within the CD34-positive or CD73/CD90/CD105-positive compartments, when combined with immunophenotyping

Testing Methods

Dye Exclusion Method (Trypan Blue and Related Dyes)

The dye exclusion principle relies on the ability of intact plasma membranes to exclude viability dyes. Trypan blue is the most widely used reagent: dead cells with damaged membranes take up the dye and appear blue, while viable cells remain unstained. Stained samples are counted manually with a hemocytometer under a microscope or processed on automated cell counters that combine bright-field imaging with image analysis. The method is fast, inexpensive, and well standardized, and it remains the reference approach described in ISO 20391-1 workflows for suspension cell counting. Its limitations include subjectivity in manual counting, inability to detect early apoptosis, and time sensitivity once dye is added.

Flow Cytometry Viability Analysis

Flow cytometry provides single-cell, multiparametric viability assessment and is the method of choice for heterogeneous stem cell products. Fluorescent DNA-binding dyes such as propidium iodide (PI), 7-aminoactinomycin D (7-AAD), and DAPI enter only cells with compromised membranes and permit rapid quantification of the dead-cell fraction. When combined with Annexin V binding, the analysis resolves four populations: viable cells, early apoptotic cells (Annexin V positive, dye negative), late apoptotic cells (double positive), and necrotic cells. Fixable amine-reactive viability dyes additionally allow viability assessment in fixed samples, and viability gating can be combined with stem cell marker staining to report viability within defined phenotypic subsets.

Metabolic Activity Assays

Metabolic assays measure functional competence rather than membrane integrity. Tetrazolium reduction assays such as MTT, XTT, and WST-1 quantify mitochondrial dehydrogenase activity through colorimetric absorbance. Resazurin (Alamar Blue) reduction provides a fluorescent readout with good sensitivity and broad dynamic range. ATP-based luminescence assays measure intracellular ATP as a surrogate for living cell biomass and are highly sensitive at low cell numbers. Metabolic results are typically reported as relative values normalized to controls, making them well suited to proliferation monitoring, cytotoxicity screening, and culture condition optimization, though they do not by themselves yield per-cell viability percentages.

Automated Imaging and Fluorescence-Based Counting

Automated cell viability analyzers combine bright-field and fluorescence channels with acoustic or lens-based focusing to count live and dead cells simultaneously using acridine orange and propidium iodide (AO/PI) or comparable dye combinations. AO stains all nucleated cells while PI stains membrane-compromised cells, enabling accurate total and viable nucleated cell counts even in samples contaminated with red blood cells or debris. These platforms improve throughput, reduce operator variability, and provide traceable digital records aligned with data integrity expectations in GMP environments.

Applications

Stem cell viability testing supports decision-making at multiple stages of the cell product lifecycle:

• Release testing for cell therapy products: viability results are verified against predefined acceptance criteria, commonly a minimum of 70% to 90% depending on product type, route of administration, and regional regulatory guidance, before a lot is approved for clinical use.
• Cryopreservation and thawing validation: comparing pre-freeze and post-thaw viability quantifies process loss and confirms the suitability of cryoprotectant formulations, controlled-rate freezing profiles, and thawing procedures.
• Cell banking quality control: master cell banks, working cell banks, and donor cell repositories rely on viability testing at deposit and at periodic requalification to demonstrate long-term stability.
• Manufacturing process optimization: viability tracking across isolation, expansion, harvest, wash, concentration, and formulation steps identifies process steps that cause cell damage and guides improvement actions.
• Shipping and logistics qualification: viability measurement before and after transport validates temperature-controlled shipping configurations and hold-time limits.
• Research and drug screening: viability assays underpin cytotoxicity testing, media comparison studies, differentiation protocol development, and pharmacological compound evaluation using stem cell models.

FAQ

What viability threshold is considered acceptable for stem cell products?

Acceptance limits depend on the intended use. Research-grade cultures are commonly expected to exceed 70% viability before experiments, while clinical cell therapy release specifications frequently require viability of at least 70% to 85%, and hematopoietic graft infusion criteria may reference specific thresholds defined by applicable transplant standards. The exact limit must be justified in the product quality dossier based on clinical and analytical data.

Which viability method should be chosen?

The choice depends on the sample and objective. Trypan blue or AO/PI automated counting is suitable for rapid, routine monitoring of suspensions. Flow cytometry is preferred when subpopulation-specific viability or apoptosis staging is required. Metabolic assays are appropriate when functional competence or relative cytotoxicity is the question of interest. For critical decisions such as lot release, an orthogonal combination of methods provides the strongest evidence.

How should samples be submitted for testing?

Samples should be transported cold but unfrozen (typically 2°C to 8°C) in sterile containers with an appropriate buffer or medium, accompanied by information on cell type, expected concentration, and collection time. Cryopreserved samples should be shipped in dry shippers or on dry ice and thawed under controlled, documented conditions immediately before analysis. Testing is best performed as soon as possible after collection, since viability declines progressively during storage.

Why can different methods give different viability values for the same sample?

Each method interrogates a different aspect of cell physiology. A cell in early apoptosis retains an intact membrane and excludes trypan blue yet shows reduced metabolic activity, producing divergent results between dye exclusion and metabolic assays. Such discrepancies are informative rather than erroneous and are the reason orthogonal confirmation is recommended for critical measurements.

Is viability the same as potency?

No. Viability indicates whether cells are alive, whereas potency reflects biological function, such as the capacity to differentiate, secrete trophic factors, or modulate immune responses. A highly viable population can still be functionally impaired. Complete quality characterization therefore pairs viability testing with identity, purity, sterility, and potency assays as part of an overall analytical control strategy.